Reappraisal of GIP Pharmacology for Metabolic Diseases.

[1]  F. Pattou,et al.  Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells. , 2016, Gastroenterology.

[2]  C. Hölscher,et al.  A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brain , 2016, Neuroreport.

[3]  C. Hölscher,et al.  Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model , 2016, Neuropharmacology.

[4]  J. Holst,et al.  Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors , 2015, British journal of pharmacology.

[5]  F. Pattou,et al.  BASIC AND TRANSLATIONAL—PANCREAS Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by a Cells , 2016 .

[6]  C. Streutker,et al.  TCF1 links GIPR signaling to the control of beta cell function and survival , 2015, Nature Medicine.

[7]  T. Müller,et al.  Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists , 2015, Molecular and Cellular Endocrinology.

[8]  P. Glazebrook,et al.  Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice. , 2015, American journal of physiology. Endocrinology and metabolism.

[9]  A. Astrup,et al.  A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. , 2015, The New England journal of medicine.

[10]  R. Seeley,et al.  A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents , 2014, Nature Medicine.

[11]  T. Hoffmann,et al.  Peptide therapeutics: current status and future directions. , 2015, Drug discovery today.

[12]  S. M. Knudsen,et al.  Functional Consequences of Glucagon-like Peptide-1 Receptor Cross-talk and Trafficking* , 2014, The Journal of Biological Chemistry.

[13]  Z. Halpern,et al.  Long-Acting Glucose-Dependent Insulinotropic Polypeptide Ameliorates Obesity-Induced Adipose Tissue Inflammation , 2014, The Journal of Immunology.

[14]  S. Al-Sabah,et al.  Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells. , 2014, European journal of pharmacology.

[15]  J. Holst,et al.  Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes , 2014, Diabetes.

[16]  M. Panhwar,et al.  A Naturally Occurring GIP Receptor Variant Undergoes Enhanced Agonist-Induced Desensitization, Which Impairs GIP Control of Adipose Insulin Sensitivity , 2014, Molecular and Cellular Biology.

[17]  Kanako Iwasaki,et al.  Chronic Reduction of GIP Secretion Alleviates Obesity and Insulin Resistance Under High-Fat Diet Conditions , 2014, Diabetes.

[18]  A. Lewis,et al.  The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. , 2014, Cell metabolism.

[19]  F. Tinahones,et al.  Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. , 2014, The Journal of clinical endocrinology and metabolism.

[20]  B. Gedulin,et al.  A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents , 2013, Diabetes, obesity & metabolism.

[21]  Bin Yang,et al.  Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans , 2013, Science Translational Medicine.

[22]  J. Holst,et al.  Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes , 2013, Diabetes Care.

[23]  D. Drucker,et al.  Emerging combinatorial hormone therapies for the treatment of obesity and T2DM , 2013, Nature Reviews Endocrinology.

[24]  N. Irwin,et al.  A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores. , 2013, Biochimica et biophysica acta.

[25]  L. Jermutus,et al.  Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide Receptor , 2013, The Journal of Biological Chemistry.

[26]  L. Groop,et al.  Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance , 2013, Diabetes.

[27]  D. McClain,et al.  MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity , 2012, Nature Medicine.

[28]  C. Mcintosh,et al.  GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis , 2012, PloS one.

[29]  H. Noda,et al.  Biological and functional characteristics of a novel low–molecular weight antagonist of glucose‐dependent insulinotropic polypeptide receptor, SKL‐14959, in vitro and in vivo , 2012, Diabetes, obesity & metabolism.

[30]  P. Pfluger,et al.  Restoration of leptin responsiveness in diet‐induced obese mice using an optimized leptin analog in combination with exendin‐4 or FGF21 , 2012, Journal of peptide science : an official publication of the European Peptide Society.

[31]  V. Mutel,et al.  Lateral Allosterism in the Glucagon Receptor Family: Glucagon-Like Peptide 1 Induces G-Protein-Coupled Receptor Heteromer Formation , 2012, Molecular Pharmacology.

[32]  C. Mcintosh,et al.  Glucose‐dependent insulinotropic polypeptide signaling in pancreatic β‐cells and adipocytes , 2012, Journal of diabetes investigation.

[33]  A. Pfeiffer,et al.  Glucose-Dependent Insulinotropic Polypeptide Reduces Fat-Specific Expression and Activity of 11β-Hydroxysteroid Dehydrogenase Type 1 and Inhibits Release of Free Fatty Acids , 2012, Diabetes.

[34]  C. Hölscher,et al.  Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice. , 2012, European journal of pharmacology.

[35]  M. Erion,et al.  Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents , 2012, Biopolymers.

[36]  J. Holst,et al.  Glucose-Dependent Insulinotropic Polypeptide , 2011, Diabetes.

[37]  J. Holst,et al.  Transgenic Rescue of Adipocyte Glucose-dependent Insulinotropic Polypeptide Receptor Expression Restores High Fat Diet-induced Body Weight Gain* , 2011, The Journal of Biological Chemistry.

[38]  J. Holst,et al.  Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes , 2011, Diabetes Care.

[39]  C. Mcintosh,et al.  Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARγ and histone acetylation , 2011, Journal of Lipid Research.

[40]  J. Holst,et al.  GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes , 2011, Diabetes.

[41]  N. Irwin,et al.  Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice. , 2011, The Journal of endocrinology.

[42]  S. Ambati,et al.  GIP-dependent expression of hypothalamic genes. , 2011, Physiological research.

[43]  Henrik,et al.  Association analyses of 249,796 individuals reveal eighteen new loci associated with body mass index , 2012 .

[44]  G. Warnock,et al.  Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion. , 2010, Gastroenterology.

[45]  T. Kieffer,et al.  Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[46]  J. Leahy,et al.  Physiologic and Pharmacologic Modulation of Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Expression in β-Cells by Peroxisome Proliferator–Activated Receptor (PPAR)-γ Signaling , 2010, Diabetes.

[47]  C. Mcintosh,et al.  A GIP Receptor Agonist Exhibits β-Cell Anti-Apoptotic Actions in Rat Models of Diabetes Resulting in Improved β-Cell Function and Glycemic Control , 2010, PloS one.

[48]  Andreas Hofmann,et al.  Glucose Intolerance and Reduced Proliferation of Pancreatic β-Cells in Transgenic Pigs With Impaired Glucose-Dependent Insulinotropic Polypeptide Function , 2010, Diabetes.

[49]  Alex Doney,et al.  Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge , 2010, Nature Genetics.

[50]  J. Fortin,et al.  Pharmacological Characterization of Human Incretin Receptor Missense Variants , 2010, Journal of Pharmacology and Experimental Therapeutics.

[51]  J. Leahy,et al.  Physiologic and Pharmacologic Modulation of GIP Receptor Expression in ß-cells by PPAR γ Signaling: Possible Mechanism for the GIP Resistance in Type 2 Diabetes , 2010 .

[52]  C. Bailey,et al.  Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. , 2009, Biochemical pharmacology.

[53]  C. Mcintosh,et al.  Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. , 2009, Human molecular genetics.

[54]  N. Irwin,et al.  Metabolic effects of sustained activation of the GLP‐1 receptor alone and in combination with background GIP receptor antagonism in high fat–fed mice , 2009, Diabetes, obesity & metabolism.

[55]  J. Egan,et al.  Exogenous Glucose–Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes , 2009, Diabetes.

[56]  N. Irwin,et al.  Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes , 2009, Biological chemistry.

[57]  T. Vilsbøll,et al.  Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes , 2009, Diabetologia.

[58]  M. Bachmann,et al.  Vaccination against GIP for the Treatment of Obesity , 2008, PloS one.

[59]  K. Polonsky,et al.  Targeted Ablation of Glucose-dependent Insulinotropic Polypeptide-producing Cells in Transgenic Mice Reduces Obesity and Insulin Resistance Induced by a High Fat Diet* , 2008, Journal of Biological Chemistry.

[60]  N. Irwin,et al.  C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. , 2008, Biochemical pharmacology.

[61]  D. Drucker,et al.  Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat–Fed Mice , 2008, Diabetes.

[62]  W. Bollag,et al.  Impact of Glucose‐Dependent Insulinotropic Peptide on Age‐Induced Bone Loss , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[63]  Yuichiro Yamada,et al.  A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice. , 2008, American journal of physiology. Endocrinology and metabolism.

[64]  J. Holst,et al.  GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. , 2007, American journal of physiology. Endocrinology and metabolism.

[65]  C. Mcintosh,et al.  Resistin Is a Key Mediator of Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Lipoprotein Lipase (LPL) Activity in Adipocytes* , 2007, Journal of Biological Chemistry.

[66]  G. Shulman,et al.  Obesity-associated improvements in metabolic profile through expansion of adipose tissue. , 2007, The Journal of clinical investigation.

[67]  P. Eriksson,et al.  Immunohistochemical distribution of glucose‐dependent insulinotropic polypeptide in the adult rat brain , 2007, Journal of neuroscience research.

[68]  N. Irwin,et al.  Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets , 2007, Diabetologia.

[69]  N. Irwin,et al.  Comparison of the subchronic antidiabetic effects of DPP IV–resistant GIP and GLP‐1 analogues in obese diabetic (ob/ob) mice , 2007, Journal of peptide science : an official publication of the European Peptide Society.

[70]  S. Bonner-Weir,et al.  Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia , 2007, Diabetes.

[71]  N. Irwin,et al.  Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice , 2007, Diabetologia.

[72]  Tanya Hansotia,et al.  Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. , 2007, The Journal of clinical investigation.

[73]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[74]  J. Holst,et al.  GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. , 2006, American journal of physiology. Endocrinology and metabolism.

[75]  J. Holst,et al.  Prohormone Convertase 1/3 Is Essential for Processing of the Glucose-dependent Insulinotropic Polypeptide Precursor* , 2006, Journal of Biological Chemistry.

[76]  M. Nauck,et al.  Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes , 2006, Diabetologia.

[77]  B. Beck,et al.  Direct metabolic effects of gastric inhibitory polypeptide (GIP): dissociation at physiological levels of effects on insulin-stimulated fatty acid and glucose incorporation in rat adipose tissue , 2006, Diabetologia.

[78]  C. Bailey,et al.  A Novel, Long-Acting Agonist of Glucose-Dependent Insulinotropic Polypeptide Suitable for Once-Daily Administration in Type 2 Diabetes , 2005, Journal of Pharmacology and Experimental Therapeutics.

[79]  C. Mcintosh,et al.  A Novel Mechanism for the Suppression of a Voltage-gated Potassium Channel by Glucose-dependent Insulinotropic Polypeptide , 2005, Journal of Biological Chemistry.

[80]  C. Bailey,et al.  Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. , 2005, Diabetes.

[81]  J. Holst,et al.  Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. , 2005, Diabetes.

[82]  C. Bailey,et al.  Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. , 2005, Journal of medicinal chemistry.

[83]  E. Wolf,et al.  Overexpression of a dominant negative GIP receptor in transgenic mice results in disturbed postnatal pancreatic islet and beta-cell development , 2005, Regulatory Peptides.

[84]  J. Holst,et al.  Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. , 2004, Diabetes.

[85]  N. Irwin,et al.  Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice , 2004, Biological chemistry.

[86]  G. Cooney,et al.  Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin , 2004, Diabetologia.

[87]  W. Creutzfeldt,et al.  Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption , 1983, Diabetologia.

[88]  T. Hansen,et al.  The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. , 2003, The Journal of clinical endocrinology and metabolism.

[89]  P. Flatt,et al.  Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo. , 2003, Metabolism: clinical and experimental.

[90]  J. Holst,et al.  Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia , 2003, Diabetologia.

[91]  R. Pederson,et al.  Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. , 2003, American journal of physiology. Endocrinology and metabolism.

[92]  J. Holst,et al.  Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[93]  C. Bailey,et al.  Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide. , 2003, The Journal of endocrinology.

[94]  P. Flatt,et al.  Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. , 2002, The Journal of endocrinology.

[95]  C. Bailey,et al.  Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. , 2002, The Biochemical journal.

[96]  R. Pederson,et al.  Glucose-dependent Insulinotropic Polypeptide Activates the Raf-Mek1/2-ERK1/2 Module via a Cyclic AMP/cAMP-dependent Protein Kinase/Rap1-mediated Pathway* , 2002, The Journal of Biological Chemistry.

[97]  C. Bailey,et al.  Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP , 2002, Diabetologia.

[98]  Yuichiro Yamada,et al.  Inhibition of gastric inhibitory polypeptide signaling prevents obesity , 2002, Nature Medicine.

[99]  R. Pederson,et al.  Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. , 2002, Diabetes.

[100]  P. Flatt,et al.  Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. , 2002, Biochemical and biophysical research communications.

[101]  R. Pederson,et al.  Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. , 2001, Diabetes.

[102]  R. Pederson,et al.  Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (betaTC-3) cells to glucose-dependent insulinotropic polypeptide. , 2000, The Journal of endocrinology.

[103]  Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance. , 2000, Advances in experimental medicine and biology.

[104]  J. Miyazaki,et al.  Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[105]  P. Flatt,et al.  NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. , 1999, Diabetes.

[106]  M. Wolfe,et al.  Functional GIP receptors are present on adipocytes. , 1998, Endocrinology.

[107]  R. Pederson,et al.  Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. , 1998, Diabetes.

[108]  D. Drucker,et al.  Effects of Aging and a High Fat Diet on Body Weight and Glucose Tolerance in Glucagon-Like Peptide-1 Receptor-/- Mice. , 1998, Endocrinology.

[109]  J. Holst,et al.  The pathogenesis of NIDDM involves a defective expression of the GIP receptor , 1997, Diabetologia.

[110]  R. Pederson,et al.  GIP6–30amide contains the high affinity binding region of GIP and is a potent inhibitor of GIP1–42action in vitro , 1997, Regulatory Peptides.

[111]  T. Usdin,et al.  Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. , 1996, The Journal of clinical investigation.

[112]  M. Wolfe,et al.  Regulation of glucose-dependent insulinotropic peptide gene expression by a glucose meal. , 1994, The American journal of physiology.

[113]  A. Turner,et al.  Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. , 1994, Endocrinology.

[114]  M. Brownstein,et al.  Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. , 1993, Endocrinology.

[115]  M. Nauck,et al.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.

[116]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[117]  D. Coy,et al.  Reduced gastric acid inhibitory effect of a pGIP(1–30)NH2 fragment with potent pancreatic amylase inhibitory activity , 1992, Regulatory Peptides.

[118]  M. Nauck,et al.  Effect of Exogenous or Endogenous Gastric Inhibitory Polypeptide (GIP) on Plasma Triglyceride Responses in Rats , 1991, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[119]  V. Marks,et al.  Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. , 1991, The Journal of endocrinology.

[120]  E. Mazzaferri,et al.  The postprandial response of gastric inhibitory polypeptide to various dietary fats in man. , 1988, Journal of the American College of Nutrition.

[121]  R. Eaton,et al.  Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. , 1986, The Journal of clinical endocrinology and metabolism.

[122]  V. Marks,et al.  Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. , 1986, Acta endocrinologica.

[123]  Graeme I. Bell,et al.  Exon duplication and divergence in the human preproglucagon gene , 1983, Nature.

[124]  P. Giacomoni,et al.  Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity. , 1982, The Journal of clinical endocrinology and metabolism.

[125]  R. Goodman,et al.  Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[126]  R. Unger,et al.  Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. , 1981, The Journal of clinical investigation.

[127]  K. Lauritsen,et al.  Gastric inhibitory polypeptide (GIP) and insulin release after small-bowel resection in man. , 1980, Scandinavian journal of gastroenterology.

[128]  R. Eckel,et al.  Gastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes , 1979, Diabetes.

[129]  J. Brown,et al.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man. , 1973, The Journal of clinical endocrinology and metabolism.

[130]  J. Brown.  A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides. , 1971, Canadian journal of biochemistry.

[131]  Brown Jc,et al.  A multiparameter study on the action of preparations containing cholecystokinin-pancreozymin. , 1970 .

[132]  H. Elrick,et al.  PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION. , 1964, The Journal of clinical endocrinology and metabolism.

[133]  N. Mcintyre,et al.  NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE. , 1964, Lancet.

[134]  J. B. Collip,et al.  Pancreatic Extracts in The Treatment of Diabetes Mellitus , 1922, Diabetes.

[135]  E. S. Edie,et al.  On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane. , 1906, The Biochemical journal.

[136]  W M Bayliss,et al.  The mechanism of pancreatic secretion , 1902, The Journal of physiology.

[137]  M. Bernard.  DEFECT OF ORGANIZATION IN THE EXTERNAL EAR. , 1824 .